medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2017-20-160-165medsovet-2248Research ArticleЭндокринологияEndocrinologyНОВЫЙ ПРЕПАРАТ В ЭВОЛЮЦИИ ИНСУЛИНОВ ДЛИТЕЛЬНОГО ДЕЙСТВИЯNEW DRUG IN THE EVOLUTION OF LONG-ACTING INSULINSКононенкоИ. В.KononenkoI. V.

кандидат медицинских наук.

Москва. 

PhD in medicine.

Moscow.

СмирноваО. М.SmirnovaO. M.

доктор медицинских наук, профессор.

Москва. 

MD, Prof.

Moscow.

Эндокринологический научный центр Минздрава России; Первый Московский государственный медицинский университет им. И.М. Сеченова.РоссияEndocrinology Research Center of the Ministry of Health of Russia; Sechenov First Moscow State Medical University.Russian Federation201707012018020160165Copyright © Кононенко И.В., Смирнова О.М., 20182018Кононенко И.В., Смирнова О.М.Kononenko I.V., Smirnova O.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2248

Инсулин гларгин, синтезированный с помощью рекомбинантной ДНК-технологии в концентрации 100 Ед/мл, был первым аналогом инсулиндлительного действия, вводимым 1 раз в день, и был применен в клинической практике в 2000 г. Гларгин доказал свою эффективность и безопасность и в настоящее время широко назначается во всем мире. В феврале 2015 г. препарат утратил свою патентную защиту в США, что открыло двери для производства биосимиляров.

Insulin glargine, synthesized using recombinant DNA technology in a concentration of 100 U/ml, was the first once-daily longacting insulin analogue introduced into clinical practice in 2000. Glargin has a well-established record of efficacy and safety and is the most widely used insulin worldwide. In February 2015, the drug lost its US patent protection, which opened the door for biosimilar competitors.

сахарный диабетинсулинотерапияинсулины продленного действияdiabetes mellitusinsulin therapylong-acting insulinReferencesСахарный диабет. Диагностика, лечение, профилактика. Под редакцией И.И. Дедова, М.В. Шестаковой. МИА, Москва, 2011.Сахарный диабет. Диагностика, лечение, профилактика. Под редакцией И.И. Дедова, М.В. Шестаковой. МИА, Москва, 2011.Инсулинотерапия. Пособие для врачей. Под редакцией И.И. Дедова. Москва, 2003.Инсулинотерапия. Пособие для врачей. Под редакцией И.И. Дедова. Москва, 2003.Bolli GB, Owens DR. Insulin glargine. Lancet, 2000, 356: 443-445.Bolli GB, Owens DR. Insulin glargine. Lancet, 2000, 356: 443-445.Rosenstock J, Dailey G, Massi-Benedetti M et al. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care, 2005, 28: 950-955.Rosenstock J, Dailey G, Massi-Benedetti M et al. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care, 2005, 28: 950-955.Lamos EM, Younk LM, Davis SN. Concentrated insulins: the new basal insulins. Therapeutics and Clinical Risk Management, 2016, 12: 389-400.Lamos EM, Younk LM, Davis SN. Concentrated insulins: the new basal insulins. Therapeutics and Clinical Risk Management, 2016, 12: 389-400.Wang F, Zassman S, Goldberg PA. rDNA insulin glargine U300 – a critical appraisal. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2016, 9: 425-441.Wang F, Zassman S, Goldberg PA. rDNA insulin glargine U300 – a critical appraisal. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2016, 9: 425-441.New insulin Glargin 300U/ml for the treatment of type I and type 2 Diabetes mellitus. Jennifer Goldman and John R White. Annals of Pharmacolotherapy, 2015, 49(10): 1153-1161.New insulin Glargin 300U/ml for the treatment of type I and type 2 Diabetes mellitus. Jennifer Goldman and John R White. Annals of Pharmacolotherapy, 2015, 49(10): 1153-1161.Home PD, Bergenstal RM, Bolli GB, Ziemen M, Rojeski M, Espinasse M, Riddle MC. New Insulin Glargine 300Units/mL versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4). Diabetes Care, 2015, 38: 22172225. DOI: 10.2337/dc15-0249.Home PD, Bergenstal RM, Bolli GB, Ziemen M, Rojeski M, Espinasse M, Riddle MC. New Insulin Glargine 300Units/mL versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4). Diabetes Care, 2015, 38: 22172225. DOI: 10.2337/dc15-0249.Matsuhisa M, Koyama M, Cheng X, Shimizu S, Hirose T, on behalf of the EDITION JP 1 study group. New insulin glargine 300 U/mL: glycaemic control and hypoglycaemia in Japanese people with type 1 diabetes mellitus (EDITION JP 1). 50th Annual meeting of the European Association for the Study Diabetes, Vienna, Austria, 15–19 September 2014. 2014: Abstract 975.Matsuhisa M, Koyama M, Cheng X, Shimizu S, Hirose T, on behalf of the EDITION JP 1 study group. New insulin glargine 300 U/mL: glycaemic control and hypoglycaemia in Japanese people with type 1 diabetes mellitus (EDITION JP 1). 50th Annual meeting of the European Association for the Study Diabetes, Vienna, Austria, 15–19 September 2014. 2014: Abstract 975.Дедов И.И., Шестакова М.В., Галстян Г.Р. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом (7-й вып.). Сахарный диабет, 2015, 18(1S): 1–112.Дедов И.И., Шестакова М.В., Галстян Г.Р. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом (7-й вып.). Сахарный диабет, 2015, 18(1S): 1–112.Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF and Paul SK, for the 4-T Study Group. Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes. N Engl J Med, 2009, 361: 1736-47.Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF and Paul SK, for the 4-T Study Group. Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes. N Engl J Med, 2009, 361: 1736-47.Standards of Medical Care in Diabetes. Pharmacologic Approaches to Glycemic Treatment. Diabetes Care, 2017, 40(Suppl. 1): S64–S74. DOI: 10.2337/dc17-S011.Standards of Medical Care in Diabetes. Pharmacologic Approaches to Glycemic Treatment. Diabetes Care, 2017, 40(Suppl. 1): S64–S74. DOI: 10.2337/dc17-S011.Ritzel R, Roussel R, Bolli GB et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes. Metab., 2015, 17(9): 859–867.Ritzel R, Roussel R, Bolli GB et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes. Metab., 2015, 17(9): 859–867.Riddle MC, Bolli GB, Ziemen M et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care, 2014, 37(10): 2755–2762.Riddle MC, Bolli GB, Ziemen M et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care, 2014, 37(10): 2755–2762.Yki-Jarvinen H, Bergenstal R, Ziemen M et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care, 2014, 37(12): 3235–3243.Yki-Jarvinen H, Bergenstal R, Ziemen M et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care, 2014, 37(12): 3235–3243.Bolli GB, Riddle MC, Bergenstal RM et al. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes. Metab., 2015, 17(4): 386–394.Bolli GB, Riddle MC, Bergenstal RM et al. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes. Metab., 2015, 17(4): 386–394.Terauchi Y, Koyama M, Cheng X, Shimizu S, Hirose T, on behalf of the EDITION JP 2 study group. Glycaemic control and hypoglycaemia in Japanese people with type 2 diabetes mellitus receiving new insulin glargine 300 U/mL in combination with OADs (EDITION JP 2). 50th Annual meeting of the European Association for the Study Diabetes, Vienna, Austria, 15-19 September 2014. 2014: Abstract 976.Terauchi Y, Koyama M, Cheng X, Shimizu S, Hirose T, on behalf of the EDITION JP 2 study group. Glycaemic control and hypoglycaemia in Japanese people with type 2 diabetes mellitus receiving new insulin glargine 300 U/mL in combination with OADs (EDITION JP 2). 50th Annual meeting of the European Association for the Study Diabetes, Vienna, Austria, 15-19 September 2014. 2014: Abstract 976.Becker RH, Nowotny I, Teichert L et al. Low within- and between-day variability in exposure to new insulin glargine 300 U/ml. Diabetes Obes. Metab., 2015, 17(3): 261–267.Becker RH, Nowotny I, Teichert L et al. Low within- and between-day variability in exposure to new insulin glargine 300 U/ml. Diabetes Obes. Metab., 2015, 17(3): 261–267.Bolli GB and DeVries JH. New Long-Acting Insulin Analogs: From Clamp Studies to Clinical Practice. Diabetes Care, 2015, 38: 541– 543. DOI: 10.2337/dc14-2314.Bolli GB and DeVries JH. New Long-Acting Insulin Analogs: From Clamp Studies to Clinical Practice. Diabetes Care, 2015, 38: 541– 543. DOI: 10.2337/dc14-2314.Becker RH, Dahmen R, Bergmann K et al. New insulin glargine 300 Units/mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units/mL-1. Diabetes Care, 2015, 38(4): 637–643.Becker RH, Dahmen R, Bergmann K et al. New insulin glargine 300 Units/mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units/mL-1. Diabetes Care, 2015, 38(4): 637–643.

The authors declare that there are no conflicts of interest present.